Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 167

  • 3 901 clinical trials
  • 1 548 recruiting
  • 705 conditions
  • 31 countries

Conditions in this area

705 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma165Neoplasm158Acute myeloid leukaemia132Neoplasm malignant128Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+681

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 901 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 901 clinical trials

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on the Effects of SAR443765 and Mometasone Furoate in Adults with Chronic Rhinosinusitis with Nasal Polyps

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Myelofibrosis

Not recruiting

Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

HER2 positive breast cancer

Not recruiting

Study of trastuzumab deruxtecan treatment in patients with advanced HER2-positive breast cancer with or without brain metastases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:AstraZeneca AB

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Acute lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Dualitybio Inc.

Study on Bendamustine, Rituximab, and Acalabrutinib for Patients with Untreated Mantle Cell Lymphoma

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Bladder cancer

Not recruiting

Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Pfizer Inc.

Non-small cell lung cancer

Not recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Macrogenics Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab463 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.